All In Biotech

Drug Trial Radar · NCT01191840

Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection

A Multi-Center, Randomized, Open-Label, Comparative Study to Assess the Safety and Efficacy of a Treatment Algorithm to Reduce the Use of Vancomycin in Adult Patients With Blood Stream Infections Due to Staphylococci

Last checked: Nov 19, 2026Latest source record: Jan 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 509 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

509

Actual

Start

Feb 2011

Primary completion

Mar 4, 2017

Study completion Mar 4, 2017

Sponsor

Lead sponsor
Duke UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institutes of Health (NIH)
First posted
Aug 31, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to accurately determine the length of appropriate drug treatment for staphylococcal blood stream infection. The study seeks to address important information about the management of staphylococcal blood stream infections.

Conditions

  • Bacteremia

Interventions

  • VancomycinDrug

    Duration

  • VancomycinDrug

    Duration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cure RateTime frame: Test of cure 2 (up to approximately 42 days)
  2. Number of Participants With Serious Adverse EventsTime frame: Test of cure 2 (up to approximately 42 days)
  3. Number of Participants With Adverse Events Leading to Study Drug WithdrawalTime frame: Test of cure 2 (up to approximately 42 days)
  4. Number of Participants That Changed From Vancomycin to Another Study Antibiotic Due to an Adverse EventTime frame: Test of cure 2 (up to approximately 42 days)

Locations

15 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama, Birmingham

    Birmingham, Alabama

  • David Geffen School of Medicine UCLA

    Los Angeles, California

  • University of Colorado

    Denver, Colorado

  • University of Mass

    Worcester, Massachusetts

  • Henry Ford Hospital

    Detroit, Michigan

  • William Beaumont Hospital

    Royal Oak, Michigan

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Albert Einstein College of Medicine

    The Bronx, New York

  • Carolina Medical Center

    Charlotte, North Carolina

  • Duke University Medical Center

    Durham, North Carolina

  • Brody School of Medicine at ECU

    Greenville, North Carolina

  • Medical University of South Carolina

    Charleston, South Carolina

  • Greenville Hospital System

    Greenville, South Carolina

  • UT MD Anderson Cancer Center

    Houston, Texas

  • Fundacio Clinic Privada per a la Recera

    Barcelona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.